Human papillomavirus type 33 L1 capsid protein antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Gardasil 9
Generic Name
Human papillomavirus type 33 L1 capsid protein antigen
DrugBank Accession Number
DB10311
Background

Human papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • L1 protein, Human papillomavirus type 33 Vaccine
  • Recombinant human papillomavirus type 33 L1 protein

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to preventHuman papillomavirus (hpv) infection•••••••••••••••••••••• ••••••••••
Prevention ofInfection caused by human papillomavirus type 33••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
GARDASIL 9Human papillomavirus type 33 L1 capsid protein antigen (20 µg) + Human papillomavirus type 11 L1 capsid protein antigen (40 µg) + Human papillomavirus type 16 L1 capsid protein antigen (60 µg) + Human papillomavirus type 18 L1 capsid protein antigen (40 µg) + Human papillomavirus type 31 L1 capsid protein antigen (20 µg) + Human papillomavirus type 45 L1 capsid protein antigen (20 µg) + Human papillomavirus type 52 L1 capsid protein antigen (20 µg) + Human papillomavirus type 58 L1 capsid protein antigen (20 µg) + Human papillomavirus type 6 L1 capsid protein antigen (30 µg)Injection, suspensionIntramuscular; ParenteralMerck Sharp & Dohme B.V.2015-10-16Not applicableItaly flag
Gardasil 9Human papillomavirus type 33 L1 capsid protein antigen (20 mcg / 0.5 mL) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg / 0.5 mL) + Human papillomavirus type 16 L1 capsid protein antigen (60 mcg / 0.5 mL) + Human papillomavirus type 18 L1 capsid protein antigen (40 mcg / 0.5 mL) + Human papillomavirus type 31 L1 capsid protein antigen (20 mcg / 0.5 mL) + Human papillomavirus type 45 L1 capsid protein antigen (20 mcg / 0.5 mL) + Human papillomavirus type 52 L1 capsid protein antigen (20 mcg / 0.5 mL) + Human papillomavirus type 58 L1 capsid protein antigen (20 mcg / 0.5 mL) + Human papillomavirus type 6 L1 capsid protein antigen (30 mcg / 0.5 mL)SuspensionIntramuscularMerck Ltd.2015-03-18Not applicableCanada flag
Gardasil 9Human papillomavirus type 33 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (60 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 31 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 45 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 52 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 58 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (30 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Llc2014-12-10Not applicableUS flag
Gardasil 9Human papillomavirus type 33 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (60 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 31 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 45 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 52 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 58 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 6 L1 capsid protein antigen (30 mcg)Injection, suspensionIntramuscularMerck Sharp & Dohme B.V.2021-02-09Not applicableEU flag
GARDASIL 9Human papillomavirus type 33 L1 capsid protein antigen (20 µg) + Human papillomavirus type 11 L1 capsid protein antigen (40 µg) + Human papillomavirus type 16 L1 capsid protein antigen (60 µg) + Human papillomavirus type 18 L1 capsid protein antigen (40 µg) + Human papillomavirus type 31 L1 capsid protein antigen (20 µg) + Human papillomavirus type 45 L1 capsid protein antigen (20 µg) + Human papillomavirus type 52 L1 capsid protein antigen (20 µg) + Human papillomavirus type 58 L1 capsid protein antigen (20 µg) + Human papillomavirus type 6 L1 capsid protein antigen (30 µg)Injection, suspensionIntramuscular; ParenteralMerck Sharp & Dohme B.V.2020-01-08Not applicableItaly flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
759RAC446C
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910490
RxNav
1596931

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
Injection, suspensionIntramuscular; Parenteral
SuspensionIntramuscular
Injection, solutionIntramuscular
Injection, suspensionIntramuscular40 mcg
Injection, suspension
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at February 13, 2021 10:52